FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) is a new sphingosine-1-phosphate receptor agonist being developed for multiple sclerosis and prevention of solid organ transplant rejection. A physiologically based pharmacokinetic model was developed to predict the concentration of FTY720 in various organs of the body. Single oral and intravenous doses of FTY720 were administered to male Wistar rats, with blood and tissue sampling over 360 h analyzed by liquid chromatography/ tandem mass spectrometry. A well stirred model (perfusion ratelimited) described FTY720 kinetics in heart, lungs, spleen, muscle, kidneys, bone, and liver, with a permeability rate-limited model being required for brain, thymus, and lymph nodes. Tissue-toblood partition coefficients (R T ) ranged from 4.69 (muscle) to 41.4 (lungs). In lymph nodes and spleen, major sites for FTY720-induced changes in sequestration of lymphocytes, R T values were 22.9 and 34.7, respectively. Permeability-surface area products for brain, thymus, and lymph nodes were 39.3, 122, and 176 ml/min. Intrinsic hepatic clearance was 23,145 l/h/kg for the free drug in blood (f ub 0.000333); systemic clearance was 0.748 l/h/kg and terminal halflife was 23.4 h. The fraction orally absorbed was 71%. The model characterized well FTY720 disposition for this extensive dosing and tissue collection study in the rat. On scaling the model to dogs and humans, good agreement was found between the actual and predicted blood concentration-time profiles. More importantly, brain concentrations in dogs were well predicted from those of the rat. In absolute terms, the predictions were slightly lower than observed values, just under a 1.5-fold deviation, but the model accurately predicted the terminal elimination of FTY720 from the brain.
FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) is a new sphingosine-1-phosphate receptor agonist that is being developed for prevention of solid organ transplant rejection (Napoli, 2000) . FTY720 exerts its immunomodulatory actions by affecting lymphocyte production (Yagi et al., 2000) , trafficking Brinkmann et al., 2000 Brinkmann et al., , 2001 , infiltration (Yanagawa et al., 2000) , and apoptosis (Enosawa et al., 1996; Bohler et al., 2000; Nagahara et al., 2000) . The maximum effects of FTY720 on these immune responses are achieved at doses smaller than those producing effects against graft rejection .
Regulation of gene expression may also account for pharmacological and toxicological effects of FTY720: for instance, a 26-week pharmacology study in rats using gene chips showed that, at doses of 0.3 and 1.5 mg/kg/day, genes of B and T lymphocyte markers in blood (CD79 and CD3) were down-regulated (Novartis Pharma AG, internal communication).
The elimination of FTY720 from the body occurs mainly via metabolism. Two primary pathways metabolize FTY720: 1) phosphorylation at one of its two hydroxy groups (yielding FTY720-P) and 2) hydroxylation at the terminal methyl group (M12) (Novartis Pharma AG, internal communication). The blood clearance values for FTY720 in dogs, monkeys, and humans are 0.0617, 0.113, and 0.0433 ml/h/kg, respectively. The elucidation of the mechanism of action and pharmacodynamics of FTY720 on immune cells will necessitate the characterization of its disposition not only in blood but also in target organs such as lymph nodes, spleen, and thymus.
The objective of this work was to develop a physiologically based pharmacokinetic (PBPK) model in rats to characterize the kinetics of intraday and interday CV% ranges were 4.15 to 5.94% and 5.01 to 5.96%, respectively.
Partition Coefficients. The AUC (area under the concentration-time curves) of drug in blood and tissues was calculated by
where C i is the drug concentration at t ϭ t i and Z is the terminal slope of the concentration-time curve. The tissue-to-blood partition coefficient (R T ) for noneliminating tissues was obtained from
where AUC T , AUC V , and AUC art are derived from drug concentration versus time profiles for tissues and venous and arterial blood. This equation was used to calculate R T for lungs, heart, brain, kidneys, thymus, spleen, muscle, and lymph nodes for the 0.3 and 2 mg/kg i.v. doses. The volume of distribution at steady state (V B,ss ) was calculated as
where V T represents specific tissue volumes and E liver is the hepatic extraction ratio.
Compartmental Analysis. Arterial blood concentration-time data for FTY720 after i.v. administration of 0.3 and 2 mg/kg doses were analyzed by compartmental analysis using the computer software WinNonlin ver. 4.0 (Pharsight Corporation, Mountain View, CA).
Model Development. Local models were developed with blood and organ concentration-time data obtained after single i.v. doses of 0.3 and 2 mg/kg. Data from each tissue were first considered individually. The choice of final structural models was based upon inspection of quality of fits to the data and the Akaike information criterion. Parameter values obtained with local models were then used as initial estimates for the whole body model. The fitted parameters were tissue-to-blood partition coefficients (R T ), permeability-surface area products (PS T ), and liver intrinsic clearance (CL int ). The first-order absorption rate constant (k abs ) and fraction of drug absorbed (F abs ) were determined by adapting the i.v. PBPK model to oral data obtained after the single doses of 2.8 and 7.5 mg/kg. For the oral PBPK model, all parameters (R T , PS T , and CL int ) were maintained as constant. Only parameters k abs and F abs were optimized. To verify the linearity of FTY720 kinetics with respect to dose, blood and tissue data obtained after the single 4 mg/kg i.v. dose were superimposed on the corresponding simulated curve based upon the parameters determined with the 0.3 and 2 mg/kg doses. Single i.v. bolus doses were regarded as a 7.5-s i.v. infusion, and drug was assumed to distribute evenly in the whole vein pool once injected. Based on metabolism and clearance data (Novartis Pharma AG, internal communication), the liver was considered as the sole eliminating organ.
Local Models. FTY720 concentration-time data after i.v. doses were fitted to
Equations for well stirred organs (heart, lungs, muscle, spleen, liver, and kidneys) were
Equations for permeability rate-limited transport (brain, thymus, lymph nodes) were: 
where Q T is organ blood flow rate, V T is organ volume, X art is input from arterial blood, PS T is permeability-surface area product, R T is tissue-to-blood partition coefficient, fw T is fractional volume of vascular and/or interstitial space, V T1 is volume of blood ϩ interstitial fluid (
, and f ub is free fraction of FTY720 in blood. Organ volumes (V i ) were scaled from published data for a 250-g rat (Bernareggi and Rowland, 1991; Davies and Morris, 1993) using
where BW 1 is the rat standard body weight (250 g) and BW 2 is the actual body weight of animals used in the current study (mean 362 g). Blood flow of tissues except thymus and lymph nodes was similarly scaled using
Blood flow for thymus and lymph nodes was scaled from Cahill and Trnka (1978) . All physiologic parameters used for this analysis are listed in Table 1 . Drug concentrations for each tissue were converted to ng/ml from ng/g using tissue density.
Model Equations for Whole Body Model. The whole body PBPK model for FTY720 is depicted in Fig. 1 . It depicts the body as composed of 13 tissue compartments and 2 blood compartments (arterial and venous pools) with the lungs closing the loop. Drug is placed in the venous compartment. All equations were solved simultaneously using the maximum likelihood estimator in ADAPT II.4 (D'Argenio and Schumitzky, 1997). Although FTY720 concentrations in bone, gastrointestinal tract, and skin were not collected, these organs were included as lumped compartments representing the gastrointestinal tract-splanchnic compartment-and "rest-of-body". It was assumed that these compartments obey the distribution characteristics of a well stirred model.
Interspecies Scale-Up. The PBPK model developed for rat was scaled-up to dog and humans. Physiological values (organ volume and blood flow rate) were taken from the literature. Unbound equilibrium distribution ratio (R T u) in dogs and humans for each tissue was calculated from R T values obtained with the rat model and corresponding f ub values for each species (f ub values were 0.000241 in dogs and 0.000361 in humans). The PS T values for brain, thymus, and lymph nodes for dog and human were predicted from the measurement in rat by use of an allometric equation
where M is organ mass (or weight) and A and B are allometric coefficients. The B value of 0.67 was fixed, assuming that permeability of tissue cellular membrane and organ structure is geometrically similar among mammals.
To predict the blood concentration versus time profile for FTY720 in dogs, a first-order absorption rate constant (k abs ) and bioavailability values were taken from the results of a compartmental analysis. Because no in vitro data were available for the biotransformation of FTY720 in dogs, the intrinsic clearance in dogs (CL intD ) was calculated by nonlinear regression analysis with the whole body PBPK model, keeping all distribution parameters (R T and PS T ) identical to those from the rat after correction for binding in blood.
To predict the concentration versus time profile for FTY720 in human blood, the first-order absorption rate constant (k abs ) was taken from the results of compartmental analysis. Because no i.v. formulation for FTY720 is available for humans, we assumed that humans had the same bioavailability (F) as rats. The intrinsic clearance in humans (CL int,H ) value was calculated in two ways. First, CL int,H was predicted from the product of the human in vitro clearance determined with liver microsomes and the in vivo to in vitro CL int ratio from rats. Second, when human FTY720 concentration data became available, they were used to improve the estimate of human CL int,H , keeping all distribution parameters (R T and PS T ) identical to those from the rat after correction for binding in blood.
Results
Blood Profiles. Figures 2 and 3 depict blood concentration-time profiles for FTY720 after i.v. and oral administration. It appears from the graphs that the model captured the venous blood concentrationtime profiles relatively well for the 0.3, 2, and 4 mg/kg i.v. doses. In contrast, arterial concentration-time profiles were somewhat overestimated. Venous blood concentration-time profiles for the 2.8 and 7.5 mg/kg oral doses were also well captured by the PBPK model. The model yielded a liver intrinsic clearance (CL int ) value based upon free FTY720 concentrations in blood of 23,145 l/h/kg. The corresponding systemic clearance value, according to the well stirred model, was 0.748 l/h/kg (f ub ϭ 0.000333). After oral administration, the first- Well Stirred Organs. Concentration versus time profiles for heart, lungs, liver, kidneys, muscle, fat, and spleen captured by the PBPK model are depicted in Figs. 4 to 7. Concentration-time curves of these organs declined in parallel with that of venous and arterial blood. Tissue-to-blood partition coefficients (R T ) calculated by noncompartmental analysis and those obtained with the PBPK model are reported in Tables 2 and 3 . Model-defined R T values were obtained with relatively good precision, with CV% on parameters generally Ͻ20%. In most organs, the deviation between the noncompartmental and PBPK-defined R T values never exceeded 3-fold. Among these well stirred organs, FTY720 distributed most extensively into lungs and liver. The extent of distribution into fat and skeletal muscle was moderate.
Permeability-Limited Organs. The concentration-time curves for FTY720 in lymph nodes, brain, and thymus are shown in Figs. 3, 4 , and 6. The model captured the observed data fairly well, with the exception of thymus, for which an overprediction of tissue concentration levels was noticed. Nevertheless, the model still captured the trend in the data as well as the terminal slope of the drug in that organ.
To develop the organ model for lymph nodes, it was assumed that fractional volumes of vascular and interstitial spaces were identical to those of thymus because the two organs belong to the immune system. The PBPK model captured fairly well the features of the data. Tissueto-blood partition coefficient values were 22.9 for lymph nodes, 27.1 for brain, and 15.7 for thymus. The corresponding PS T values were 176, 39.3, and 122 ml/min (Table 3) . Other Organs. Organs that were not sampled, such as bone and skin, were lumped into a single compartment labeled "rest of body". A nonsampled splanchnic compartment comprising stomach and intestinal tract was also incorporated to account for the flow of blood dmd.aspetjournals.org through the liver. The model-predicted R T values were 50.9 for the rest-of-body and 11.1 for the splanchnic compartment. Being unobserved, these tissue-to-blood partition coefficients may not reflect the real extent of FTY720 distribution in these organs.
Prediction of FTY720 Kinetics in Dogs and Humans. Figure 8 depicts FTY720 blood concentration-time profile in the dog after i.v. (Fig. 8, top) and oral (Fig. 8, middle) administration. The PBPK model was able to capture the experimental data reasonably well. Despite an overestimation of C max after oral administration, the model described the terminal slope with good accuracy. FTY720 concentrations in dog brain were simulated for a single oral dose of 10 mg/kg. We used the appropriate dog physiology and the extrapolated organ distribution parameters from the whole body PBPK model. As shown in Fig. 8 (bottom) , the predictions were slightly lower than the observed values, by just under 1.5-fold, but the model predicted accurately the slope of decay of FTY720. Figure 9a shows the FTY720 concentration-time profile in human blood after a single oral dose of 1 mg, as predicted from the rat PBPK model with the in vitro intrinsic clearance determined from human liver microsomes. Although the prediction was not perfect, it was within interindividual variability. It was noted that the predicted C max value for FTY720 was different from the observed values. Figure 9b shows the FTY720 concentrations in human blood obtained after optimizing the intrinsic clearance to fit the human data. A great improvement was observed and the observed concentration data were better described by the PBPK model.
Discussion
The present analysis characterizes the concentration-time profiles for FTY720 in venous and arterial blood and in an extensive array of organs after i.v. and oral administration to rats. Gaining insight into the pharmacokinetic behavior of a drug in different organs is highly desirable, especially in therapeutic target organs or those for which the compound may be potentially harmful. We were able to analyze FTY720 concentration versus time profiles in the typical major organs, but also in other rather unusual ones, viz. lymph nodes, spleen, and thymus. FTY720 is an immunomodulator that exerts its pharmacological action by sequestering lymphocytes in secondary immune organs. Thus, being able to characterize the behavior of the drug in pharmacological targets such as spleen and lymph nodes constitutes a unique achievement.
There are several advantages of developing PBPK models. Two obvious advantages are the possibility to investigate, in animals, organs that could otherwise never be assessed in humans, and the possibility to extrapolate the model to higher species by adjusting organ volumes and perfusion rates, and adjusting for differences in metabolism, plasma protein binding, and blood cell distribution between species.
The results of the investigation showed that FTY720 distributed extensively into various organs. More importantly, distribution and clearance appeared to be linear in the dose range of 0.3 to 4 mg/kg. The model-predicted R T values were similar to those calculated by noncompartmental analysis. On average, a 3-fold deviation was observed between the two analyses ( Table 2 versus Table 3 ). Brain, lymph nodes, and thymus concentration-time data could be described by the permeability-limited model only. Although this model seems natural for brain because of the blood-brain barrier to xenobiotics, the applicability to lymph nodes and thymus is less clear. To our knowledge, specific cell membrane resistance to drug transport into thymus or lymph nodes has not been documented. The PS T values for lymph nodes, brain, and thymus translate to transfer clearance (i.e., product of PS T and f ub ) values of 0.058, 0.0131, and 0.048 ml/min, respectively. These transfer clearances are all smaller than the corresponding organ blood flows (Table 1) . Thus, modeling FTY720 kinetics in these tissues using a permeability-limited model was warranted.
There were some discrepancies between tissue binding parameters obtained with local and whole body models. Several reasons may explain these differences. First, each organ in the body is, in fact, in equilibrium with the blood leaving the organ, rather than with the measured venous blood as assumed in the local models. This discrepancy is even more pronounced for the lungs, which are in equilibrium with the arterial blood. Second, in the determination of local organ parameters, we used observed venous blood concentration, whereas the whole body model takes into account the model-predicted blood concentration. As can be seen in Fig. 2 , the predicted venous blood concentrations after the bolus administration are higher than the observed data, especially for the lower dose of 0.3 mg/kg.
The volume of distribution at steady state estimated with eq. 3 yielded a value of 8.61 l/kg. This figure is close to the one obtained by a standard compartmental analysis (13.7 l/kg, Table 4 ). The intrinsic clearance estimated by the current model was 23,145 l/h/kg. This value seems very large. However, because FTY720 is highly bound to plasma proteins (Novartis Pharma AG, internal communication) and distributes extensively into red blood cells, this intrinsic clearance corresponded to a systemic clearance value of 0.748 l/h/kg. This value was not too different from the average systemic clearance obtained by compartmental analysis (0.497 l/h/kg, Table 4 ). Due to strong binding to blood components, extensive distribution, and a relatively low systemic clearance, FTY720 has a half-life of about 20 h in rats (Table 4) .
In the development of the PBPK model, it was assumed that FTY720 is eliminated from the body by metabolic biotransformation occurring mostly in the liver. This assumption was based on the fact that no parent drug could be detected in urine samples. One complication in FTY720 metabolism is that the compound undergoes reversible metabolism (Novartis Pharma AG, internal communication). Interconversion between FTY720 and its phosphorylated metabolite (FTY720-P) is catalyzed by type 1 and 2 sphingosine kinases. These enzymes are found in numerous tissues including liver, eye, lung, and muscle. The characterization of reversible systems can be achieved only after collecting concentration-time data of parent and metabolite after separate i.v. administration of parent and metabolite (Cheng and Jusko, 1993) . No metabolite concentration data were measured in the present study. Therefore, the present PBPK model may only be an approximation of FTY720 kinetics in blood and organs because reversible metabolic processes were not taken into account. Interest in FTY720-P is high; it is the pharmacologically active moiety. However, with an equilibrium between FTY720 and FTY720-P, R T and PS T will be apparent parameters incorporating both partition-diffusion to and from tissues, together with reversible metabolic interconversion. The rapidity of the achievement of an equilibrium between FTY and FTY-P may explain why a model of the parent works well for characterizing the pharmacodynamics of lymphocyte trafficking in monkeys (Li et al., 2002 ). The PBPK model was able to mimic blood concentration-time profiles in dogs after oral and i.v. administration when optimizing only the intrinsic clearance and maintaining the tissue binding parameters from the rat. In addition, we were able to test the model prediction of brain concentrations in dogs. Although the predictions were slightly lower than the observed values, the model predicted accurately the slope of decay of FTY720 in dog brain. This may allow the determination of the half-life in this organ in the dog as well as other species. These observations gave some confidence in the plausibility of the model. In the evaluation of human data, we observed that using the scaled intrinsic clearance from in vitro data was not optimum. This may stem from the rather complex metabolic pathways of FTY720, which might not occur solely in liver microsomes as the in vitro data assumes. Nevertheless, after optimization of the human CL int , the model was able to capture the observed data quite well (Fig. 9b) .
The PBPK approach allows one to have insight into drug kinetics in organs and tissues that are not accessible in humans because of technical and ethical reasons. The PBPK model worked well to characterize FTY720 properties for this extensive dosing and tissue collection study. On scaling the model to dogs and humans, good agreement was found between the actual and predicted blood concentration-time profiles. More importantly, a prediction of brain concentrations in dogs based upon the rat model was checked against observed data. The predictions were slightly lower than the observed values (less than a 1.5-fold deviation), but the model accurately predicted the slope of decay of FTY720 concentrations in dog brain.
We have shown in the current analysis that because of the good description of FTY720 in human blood and dog brain, one can have some confidence in simulated drug concentration-time profiles in organs of interest in humans. FTY720 is currently considered for additional indications such as multiple sclerosis, for which the kinetics of the drug in the brain is of great relevance.
In conclusion, a PBPK model for FTY720 was developed to account for the time course of drug concentrations in blood and a large array of tissues including lymph nodes and other tissues, which are seldom studied. The studies encompassed three i.v. and two oral doses and showed linear distribution and elimination kinetics. Appreciable and variable tissue binding was found, but the PBPK model functioned well to describe the properties of FTY720. 
